Acumen Pharmaceuticals (ABOS) Shares Outstanding (2020 - 2026)
Acumen Pharmaceuticals (ABOS) posted Shares Outstanding (Entity) of $72.2 million for Q1 2026, up 19.24% sequentially from $60.6 million in Q4 2025, and up 19.24% YoY from $60.6 million in Q1 2025.
Acumen Pharmaceuticals (ABOS) Shares Outstanding (2020 - 2026) Analysis & Trends
Acumen Pharmaceuticals has reported Shares Outstanding (Entity) for 7 years, with the latest figure at $72.2 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 19.24% year-over-year to $72.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $72.2 million (up 19.24% YoY) and the FY2025 annual result came in at $60.6 million, up 0.8% from the prior year.
- Shares Outstanding (Entity) climbed to $72.2 million in Q1 2026 per ABOS's latest filing, from $60.6 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $72.2 million in Q1 2026 and troughed at $40.5 million in Q1 2022.
- A 5-year average of $53.8 million and a median of $60.1 million in 2024 frame the typical range for Shares Outstanding (Entity).
- The widest YoY moves for Shares Outstanding (Entity): up 9556.63% in 2022, down 0.08% in 2022.
- Over 5 years, Shares Outstanding (Entity) stood at $41.0 million in 2022, then soared by 41.16% to $57.9 million in 2023, then grew by 3.77% to $60.1 million in 2024, then gained by 0.8% to $60.6 million in 2025, then rose by 19.24% to $72.2 million in 2026.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $72.2 million, $60.6 million, and $60.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Acumen Pharmaceuticals | 226.87 Mn | 226.87 Mn | - | 72.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 63.22 Mn |
| Mar 31, 2026 | 63.22 Mn |
| Dec 31, 2025 | 60.56 Mn |
| Sep 30, 2025 | 60.57 Mn |
| Jun 30, 2025 | 60.57 Mn |
| Mar 31, 2025 | 60.53 Mn |
| Dec 31, 2024 | 60.01 Mn |
| Sep 30, 2024 | 60.08 Mn |
| Jun 30, 2024 | 60.08 Mn |
| Mar 31, 2024 | 59.81 Mn |
| Dec 31, 2023 | 48.61 Mn |
| Sep 30, 2023 | 54.23 Mn |
| Jun 30, 2023 | 41.03 Mn |
| Mar 31, 2023 | 41.03 Mn |
| Dec 31, 2022 | 40.60 Mn |
| Sep 30, 2022 | 40.50 Mn |
| Jun 30, 2022 | 40.50 Mn |
| Mar 31, 2022 | 40.47 Mn |
| Dec 31, 2021 | 20.06 Mn |
| Sep 30, 2021 | 38.27 Mn |